# Spirax Group reports 5% first-half revenue growth, reiterates 2026 guidance

- Link: https://www.directorstalkinterviews.com/spirax-group-reports-5-first-half-revenue-growth-reiterates-2026-guidance/4121260041
- Published: 2026-08-11T07:19:00+01:00
- Author: Amilia Stone

**Spirax Group PLC** (LON:SPX) has announced its 2026 Half Year Results

_First half in line; on track to deliver full year guidance_

**Six months ended 30 June**

| **Statutory (£m/p)** | **2026** | **2025** | **Reported** | 
| Revenue^(1) | 863.8 | 822.2 | 5% | 
| Operating profit | 154.2 | 106.8 | 44% | 
| Operating profit margin | 17.9% | 13.0% | 490bps | 
| Profit before taxation | 135.4 | 87.9 | 54% | 
| Basic earnings per share | 132.2 | 85.0 | 56% | 
| Dividend per share | 50.4 | 48.9 | 3% |

| **Adjusted**^(7) **(£m/p)** | **2026** | **2025** | **Reported** | **Organic**^(2) | 
| Revenue^(1) | 863.8 | 822.2 | 5% | 5% | 
| Adjusted operating profit | 171.1 | 158.8 | 8% | 6% | 
| Adjusted operating profit margin | 19.8% | 19.3% | 50bps | 10bps | 
| Adjusted profit before taxation | 152.3 | 139.9 | 9% |  | 
| Adjusted basic earnings per share | 150.0 | 137.6 | 9% |  | 
| Adjusted cash conversion | 54% | 61% | (700)bps |  |

| **●** | Group revenue up 5% ^(3) and well ahead of IP^(5) of 1.5%; margin up 10bps^(3) | 
| **●** | STS^(4) sales up 1%^(3) with demand growth of over 2x IP; strong orderbook and momentum into second half | 
| **●** | ETS^(4) sales up 11%^(3) with strong demand growth across all three Divisions | 
| **●** | WMFTS^(4) sales up 7% ^(3) with Biopharm^(6) orders ahead of sales and continuing growth in PI^(6)   | 
| **●** | STS margin^(3) reflects phasing of shipments and investment in growth; full year broadly in line with 2025 | 
| **●** | ETS and WMFTS margins up strongly^(3) benefiting from operating leverage, mix and operational efficiencies | 
| **●** | Statutory operating profit up 44% and margin up 490bps due to one-off restructuring costs in 2025 | 
| **●** | Adjusted cash conversion reflects usual seasonality and planned inventory builds; ROCE up 180bps | 
| **●** | On track to deliver full year guidance: mid-single-digit organic revenue growth and organic margin progress |

> **Nimesh Patel, Group Chief Executive Officer, commenting on the results said:**
> “We have again delivered resilient mid-single-digit organic growth in revenue 
> and profit, well ahead of IP.  Driving growth ahead of our markets, in spite of
> external conditions, is now becoming embedded in how we operate and demonstrates
> the strengths of our business model and strategic positioning in diversified and
> attractive end markets.  
> “Continuing momentum in end markets such as Semicon and Biopharm as well as strong
> orderbooks, underpin our expectations for second half revenue and profit growth
> and we are reiterating our full year guidance. 
> “Our Together for Growth Strategy is strengthening the Group’s differentiated 
> business model, competitive leadership and resilience to drive sustained compounding
> organic growth at high margins and improving returns on capital.  We remain on
> track to deliver the medium-term targets we set out for the Group in October 2024;
> and above these targets in the longer term.”

http://www.rns-pdf.londonstockexchange.com/rns/0289Q_1-2026-8-10.pdf

^(1) ‘Sales’ is used interchangeably with ‘revenue’ when describing the financial
performance of the Group

^(2) ‘Organic measures are at constant currency and exclude contributions from acquisitions
and disposals

^(3) Period on period changes are stated on an organic basis

^(4) ‘STS’: Steam Thermal Solutions; ‘ETS’: Electric Thermal Solutions; ‘WMFTS’:
Watson-Marlow Fluid Technology Solutions

^(5) ‘IP’: Industrial Production growth excluding China (June 2026)

^(6) ‘Semicon’: semicon wafer fab equipment manufacturers; ‘Biopharm’: Pharmaceutical&
Biotechnology sector; ‘PI’: Process Industries

^(7) See Appendix to the Financial Statements for an explanation of alternative 
performance measures and reconciliation to IFRS measures^()

[0289Q_1-2026-8-10](https://www.directorstalkinterviews.com/wp-content/uploads/2026/08/0289Q_1-2026-8-10.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/08/0289Q_1-2026-8-10.pdf)

Share on:
